Canine platelet-rich plasma injectable gets FDA clearanceApril 30, 2024The off-the-shelf product is intended to provide a canine-specific source of concentrated platelets in plasma for intra-articular administration in dogs.
SPONSORED CONTENTA brighter future for parvovirus patientsOur Canine Parvovirus Monoclonal Antibody helps puppies recover faster, and current users report reductions in clinic stress during parvo treatment.1,2 Find out why veterinary teams are embracing CPMA. + Read More
Researchers review mesenchymal stem cell therapy potentialApril 18, 2018 In a review published in the Journal of Feline Medicine and Surgery, Jessica M. Quimby, DVM, Ph.D., DACVIM, Department of Veterinary Clinical Sciences at The Ohio State University, and Dori L. Borjesson, DVM, MPVM, Ph.D., Veterinary Institute for Regenerative Cures at the University of California, Davis, consider both the current and potential clinical applications of mesenchymal stem cell therapy in cats. The use of bone marrow-derived stem cells is established for the treatment of human cancer patients and, as such, veterinary applications for bone marrow- and adipose-derived stem cells are being evaluated. In their review, Drs. Quimby and Borjesson consider the emergence of this trend, as well as the current understanding of the biology/immunology of mesenchymal stem cells. Additionally, the authors analyze previous use of mesenchymal stem cells in the treatment of a number of inflammatory, degenerative, and immune-mediated diseases of cats. Traditionally, managing such conditions relies on a lifelong use of medication, with the potential for associated side effects. Often, cats do not respond to standard treatment strategies and, thus, the medication may not protect against the progression of the underlying disease. So far, applications of mesenchymal stem cell therapy in cats have produced encouraging results, including …
BodeVet, distributor partners prepare to launch StablePlate RXMarch 29, 2018BodeVet, a company that develops novel blood products for use in hemostasis and regenerative medicine for the veterinary industry, has partnered with Blue Ridge Veterinary Blood Bank, HemoSolutions, and Northwest Veterinary Blood Bank to support distribution of its first product, StablePlate RX. Billed as the world's first injectable freeze-dried platelet derived product, StablePlate RX Canine is used to treat acute uncontrolled hemorrhage in bleeding canine patients, according to Anne Hale, DVM, chief technical officer for the Rockville, Md., company. Last year, BluePearl Veterinary Partners, Friendship Animal Hospital, Cornell University, the University of Georgia, and Iowa State University participated in clinical trials; Ethos Veterinary Health and North Carolina State University recently joined the clinical trial group, as well. Findings are to be released later this year. For more information on BodeVet, StablePlate RX, or its team of experts in veterinary transfusion medicine, visit bodevet.com.
